For patients with type 2 diabetes

Levemir® (insulin detemir [rDNA origin] injection) demonstrated significantly less weight gain vs insulin glargine1,2

A 52-week, multinational, open-label, parallel-group, treat-to-target trial using a noninferiority design. Subjects diagnosed with type 2 diabetes ≥12 months on any OAD (oral antidiabetic) therapy or on any insulin regimen with or without OAD therapy for >4 months were randomized 2:1 to the Levemir® and insulin glargine treatment arms, respectively. A total of 323 patients were randomized; 257 completed the study. In both treatment groups, insulin aspart was administered as a mealtime insulin.2

Adapted from Hollander et al, 2008.2

  • In another study, patients taking Levemir® (insulin detemir [rDNA origin] injection) experienced 23% less weight gain vs patients taking insulin glargine (+6.6 lb vs +8.6 lb, respectively; P=0.01)1

Patients with higher BMI experienced less weight gain3

Results in low FPG target group (70-90 mg/dL)3

Results from a 20-week randomized, controlled, multicenter, open-label, parallel-group, treat-to-target trial using a physician-directed self-titration algorithm in insulin-naïve patients with type 2 diabetes. A1C ≥ 7% and ≤ 9% on OAD therapy randomized to Levemir® and OAD (1:1) to 2 different FPG titration targets (70-90 mg/dL [n=122] or 80-110 mg/dL [n=122]). Subgroup with BMI > 40 not shown.3

Adapted from Blonde et al, 2009.3

Levemir® demonstrated significantly less weight gain vs NPH insulin4

Significantly less weight gain4

Hermansen et al, a 24-week, randomized, multicenter, open-label, parallel-group, treat-to-target trial in insulin-naïve patients with type 2 diabetes currently taking 1 or 2 OADs. Patients were randomized to either twice-daily Levemir® (n=227) or NPH insulin (n=225).4

Adapted from Hermansen et al.4

The significant weight difference vs NPH insulin was seen across multiple studies4-7

A significant weight difference with Levemir® (insulin detemir [rDNA origin] injection) across multiple studies

  • 45% less weight gain after 26 weeks in Haak et al (Levemir®: +2.2 lb; NPH insulin: +4.0 lb [P=0.017])*
  • 57% less weight gain after 20 weeks in Philis-Tsimikas et al (Levemir®: +1.5 lb; NPH insulin: +3.5 lb [P=0.005])
  • 56% less weight gain after 22 weeks in Rašlová et al (Levemir®: +1.1 lb; NPH insulin: +2.5 lb [P=0.038])

*Haak et al, a 26-week, randomized, multicenter, open-label, parallel-group trial in patients with type 2 diabetes of duration >12 months and insulin treatment duration of at least 2 months. Patients were randomized 2:1 to either once- or twice-daily Levemir® (n=341) or NPH insulin (n=164) as part of basal-bolus therapy with NovoLog®.5

Philis-Tsimikas et al, a 20-week, randomized, multicenter, open-label, parallel-group trial in insulin-naïve type 2 diabetes patients who were uncontrolled on 1 or 2 OADs. Patients were randomized to once-daily Levemir® AM administration (n=168), once-daily Levemir® PM administration (n=170), or NPH insulin (n=166).6

Rašlová et al, a 22-week, randomized, multicenter, open-label, parallel-group trial in patients with type 2 diabetes. Patients were randomized to 1 of 2 basal-bolus regimens: once- or twice-daily Levemir® plus NovoLog® (n=195) or NPH insulin plus regular human insulin (n=199).7